Upstream Bio (UPB) Total Liabilities (2023 - 2026)
Upstream Bio (UPB) posted quarterly Total Liabilities of $14.1 million for Q1 2026, up 33.15% year-over-year from $10.6 million in Q1 2025, and little changed quarter-over-quarter from $14.0 million in Q4 2025.
Upstream Bio (UPB) Total Liabilities (2023 - 2026) Analysis & Trends
Upstream Bio's Total Liabilities history runs 4 years deep, the most recent figure standing at $14.1 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 33.15% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $14.1 million (up 33.15% YoY), while the FY2025 annual figure was $14.0 million, up 17.98% from the prior year.
- Total Liabilities for Q1 2026 stood at $14.1 million, roughly flat from $14.0 million in the prior quarter.
- The five-year high for Total Liabilities was $14.1 million in Q1 2026, with the low at $9.4 million in Q4 2023.
- The 4-year median for Total Liabilities is $12.0 million (2024), against an average of $12.1 million.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities grew 3.91% in 2025, then soared 33.15% in 2026.
- Upstream Bio's Total Liabilities stood at $9.4 million in 2023, then increased by 26.39% to $11.9 million in 2024, then increased by 17.98% to $14.0 million in 2025, then advanced by 0.41% to $14.1 million in 2026.
- Business Quant data shows UPB's Total Liabilities at $14.1 million in Q1 2026, $14.0 million in Q4 2025, and $12.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 10.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.21 Mn |
| Mar 31, 2026 | 14.06 Mn |
| Dec 31, 2025 | 14.00 Mn |
| Sep 30, 2025 | 12.61 Mn |
| Jun 30, 2025 | 11.78 Mn |
| Mar 31, 2025 | 10.56 Mn |
| Dec 31, 2024 | 11.87 Mn |
| Sep 30, 2024 | 12.14 Mn |
| Dec 31, 2023 | 9.39 Mn |